IBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ImmunityBio Inc (IBRX) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown significant revenue growth, its financial performance is still weak with declining net income and EPS. The technical indicators are mixed, with bullish moving averages but a bearish MACD. Options data shows a bullish sentiment, but recent news and stock trends suggest potential downside risks. Given the lack of strong positive catalysts and the ongoing legal investigation, it is prudent to hold off on investing in IBRX for now.
The stock shows mixed signals. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the MACD histogram is negative (-0.0735) and expanding downward, indicating bearish momentum. RSI is neutral at 61.576. Key support is at 5.742, and resistance is at 6.931. The stock has a 60% chance of declining in the short term (-1.47% in the next day, -3.56% in the next week, and -13.99% in the next month).
Jefferies raised the price target to $9 from $8 and maintained a Buy rating, citing the company's execution in expanding its pipeline and geographic presence. EMA conditional marketing authorization recommendation for Anktiva in NMIBC-CIS is a positive regulatory milestone.
Ongoing investigation by Pomerantz LLP for potential securities fraud and unlawful business practices. Recent trial for recurrent glioblastoma failed to meet its primary endpoint, leading to a 12.13% stock price drop. Stock trend analysis shows a high probability of short-term declines.
In Q3 2025, revenue increased significantly by 425.07% YoY to $32.06M. However, net income dropped by 21.55% YoY to -$67.25M, and EPS declined by 41.67% YoY to -0.07. Gross margin slightly decreased to 99.45%, down by 0.55% YoY.
Jefferies maintains a Buy rating with a price target increase to $9, citing strong execution and potential regulatory approvals. However, the stock is facing significant challenges, including legal investigations and trial setbacks.
